Amyloidosis, Drug Safety, and a New Therapeutic Hope | Dr. Andy Vick
Drug development is ultimately a balancing act: can a therapy create meaningful benefit without introducing unacceptable risk?
Dr. Andy Vick joins BioTalk Unzipped to discuss systemic amyloidosis, therapeutic antibodies, diagnostics, toxicology, rare disease research, and the transition from CRO life into biotechnology.
Andy explains the biology of systemic amyloidosis and describes Attralus Therapeutics’ approach to developing biologic therapeutics and diagnostics aimed at amyloid disease.
The conversation provides an accessible introduction to toxicology and why safety evaluation is…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.